---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-24-000046"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:49:32.000295+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences reports CB-010 ANTLER Phase 1 data: 14.4 mo median PFS with partial HLA matching

## Summary
- Median PFS of 14.4 months with ≥4 HLA matches (N=13) vs 2.8 months with ≤3 matches (N=33).
- In LBCL patients with ≥4 HLA matches (N=11), median PFS not reached; ORR 91%, CR rate 36%.
- No Grade ≥3 CRS or GvHD observed; RP2D selected at 80x10^6 CAR-T cells.
- Plan to enroll ~20 additional 2L LBCL patients prospectively; initial data expected H1 2025.
- Pivotal Phase 3 trial for CB-010 in 2L LBCL planned for H2 2025 if confirmed.

## SEC filing metadata
- accession: 0001619856-24-000046
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000046/0001619856-24-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000046/crbu-20240602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-24-000046
- JSON: https://secwatch.observer/filing/0001619856-24-000046.json
- Plain text: https://secwatch.observer/filing/0001619856-24-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.